RedSail Technologies® Presents... A Customer Townhall: NRx® & Community Pharmacy
Wednesday, September 29 | 1:30 PM – 2:30 PM (ET) | Q&A to Follow
Join RedSail Technologies' leaders for a discussion on our commitment to NRx and continual innovation. Learn about recent improvements to NRx and upcoming plans. Plus, get a quick look at PioneerRx®. Stay with us after the townhall for a 45-minute breakout on the PREP Act and immunizations/reimbursements.
This live, interactive session will be hosted by: Bob Bates, EVP, RedSail Technologies and General Manager of QS/1® and Integra®; Mark Bivins, Vice President of Sales, PioneerRx; Frances Nahas, Chief Strategy Officer, RedSail Technologies; and Ed Vess, R.Ph., Director of Pharmacy Professional Affairs, RedSail Technologies
QS/1 will be at NCPA® 2021! Will you be attending?
PREP Act Extended to Influenza Vaccines
HHS Secretary Xavier Becerra issued an amendment to the federal Public Readiness and Emergency Preparedness (PREP) Act that extends coverage to pharmacy technicians and interns with proper training (similar to previous requirements to administer COVID-19 and childhood vaccines) to administer seasonal flu vaccines to adults. As of August 4, 2021, qualified pharmacy technicians and pharmacy interns (under the supervision of a state-licensed pharmacist and licensed or registered by their state board of pharmacy) can now administer seasonal influenza vaccines recommended by the Advisory Committee on Immunization to persons aged 19 and older.
Beginning November 15, 2021, healthcare professionals prescribing clozapine, pharmacists and authorized representatives of pharmacies dispensing clozapine, and wholesalers/distributors distributing clozapine must recertify or reenroll in the Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program. All stakeholders may start to recertify and reenroll now.
The REMS administrator has changed, and the current “switch” pharmacy management system is being removed as a method to verify clozapine dispensing. Pharmacists will no longer use the switch system to obtain a pre-dispense authorization, now called a REMS dispense authorization (RDA). To obtain an RDA, visit the Clozapine REMS website or call the Clozapine REMS Contact Center at 888.586.0758.
The Community Pharmacy Enhanced Services Network (CPESN) is reimagining healthcare delivery with patients at the center of care. This clinically integrated network of high-performing pharmacies is growing. Want to know more about the movement? Attend an introductory webinar hosted by a community pharmacy owner.
Healthcare continues to transition to a value-based system, and during this pandemic, community pharmacists have further proven their essential role in providing patient care. Vaccine administration has been a launching pad for some pharmacies to provide additional clinical services that improve overall patient health outcomes and increase profit margins. Watch NCPA’s 5-part video series to learn more about a business model that can both sustain and grow your pharmacy.
Rethink Pharmacy Videos:
The 4 Tenets of the Clinical Community Pharmacist
The Role of Technology in Patient Care
Be Intentional in Your Marketing
New Models of Payment – Population Health Management
New Models of Payment – Connecting to the Clinical Community
RedSail continues to implement process improvements to further enhance your customer experience. As part of this effort, we want to update your existing Software License Agreement (SLA) and Business Associate Agreement (BAA) to ensure they remain compliant with the ever-changing healthcare regulatory landscape. This change will provide many benefits to you, including less paperwork going forward, easier processing, and automatic updates with new customer programs.
Note: You will have the option to opt out if any program no longer meets your needs.
If you haven’t already received an email request from OneSpan to sign the updated agreements, please complete this form to initiate the process.
Currently, the Centers for Disease Control and Prevention (CDC) is recommending that moderately to severely immunocompromised people receive an additional vaccine dose. This includes people who have:
Been receiving active cancer treatment for tumors or cancers of the blood
Received an organ transplant and are taking medicine to suppress the immune system
Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
Advanced or untreated HIV infection
Active treatment with high-dose corticosteroids or other drugs that may suppress the immune response
Patients should talk to their healthcare provider about their medical condition and whether getting a booster shot is appropriate for them.
Pharmacies are encouraged to document the reason for any additional doses of COVID-19 vaccine being provided to immunocompromised patients, including how the patient meets the criteria to receive an additional dose. That can be from a patient attestation or other clinical documentation of the patient’s condition.
A self-service portal is essential to providing relevant and agile customer experiences. The best portals include knowledge base articles, the ability to create and manage support cases, and an interactive community forum. Guess what? The Hub has all that functionality and more. Visit anytime – 24/7 – to access product-specific content.
Access to the Hub requires registration. If you haven’t signed up yet, click here and complete the form.
